OSLO
Oncosil Medical Ltd
π¦πΊ ASX
π Overview
π Performance
π΅ Cost
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
N/A
Annual Growth
5 years average annual growth
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
0
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
Oncosil Medical Ltd - Option Expiring 30-Apr-2027
π Performance
Price History
N/A
1M
1Y
All Time
Graph
Table
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ΅ Costs
πΌ
N/A
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π° Price*
$0.00
*Price may be up to 24 hours old
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in OSLO
0
π Total Capital Earnings
N/A
π Average investment frequency
N/A
π΅ Average investment amount
N/A
β° Last time a customer invested in OSLO
N/A
OSLO investor breakdown
π΅ Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
πΆ Age of investors
18 - 25
26 - 34
35 - 90
π Legal gender of investors
Female
Male
Pearlers who invest in OSLO also invest in...
Want more shares? Try these...
Osmond Resources Ltd. is an early-stage mineral exploration and development company, which engages in the discoveries for gold, nickel, copper, and rare earth elements within the prospective Fowler Domain and Nuyts Domain, both within the Gawler Craton in South Australia as well as western Victoria. The company is headquartered in Melbourne, Victoria. The company went IPO on 2022-04-22. The firm's projects include Salt Wells Project, Iberian One Project, Yumbarra Project, Fowler Project, Coorabie Shear Zone Project, Tallacootra Project and Sandford Project. The Salt Wells Project is located in Churchill County, Nevada, United States. The Salt Wells Project consists of approximately 276 mineral claims, covering an area of 36 square kilometers (km2). The firm's Australian Projects (Yumbarra Project, Fowler Project, Coorabie Shear Zone Project, Tallacootra Project and Sandford Project) are focused on exploration for gold, nickel, copper and rare earth elements (REE) within the highly prospective Fowler Domain and Nuyts Domain, both within the Gawler Craton in South Australia and western Victoria. The Iberian One Project is located in Spain.
π Share price
$0.42 AUD
βοΈ MINING
Orpheus Uranium Ltd. engages in the exploration and development of minerals including gold and copper. The company is headquartered in Adelaide, South Australia. The firm is focused on uranium exploration in the two jurisdictions of Australia that permit uranium mining, South Australia and the Northern Territory. In South Australia there are five key project areas: Frome, Mundaerno, Radium Hill South, Cummins and Marree. In the Northern Territory there are four key project areas: Mount Douglas, Woolner, Alligator Rivers Uranium Field and South Alligator Valley Mineral Field. Its other projects include Higginsville, Kroombit, Aroona, Lumwana West, Kamapanda, Kalaba East, Musangila, and others. The Frome project comprises four exploration licenses covering a combined area of 3,037 square kilometers, located in the Frome Embayment of South Australia. The Mundaerno project comprises one exploration license application, EL 6958, which comprises two blocks in the Southern Curnamona Province of South Australia.
π Performance (5Yr p.a)
185.00%
π Share price
$0.04 AUD
βοΈ MINING
OncoSil Medical Ltd. develops and commercializes neurology services, including those for pancreatic cancer. The company is headquartered in Macquarie, New South Wales. The company went IPO on 2005-08-15. The firm is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The firm has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.
π Performance (5Yr p.a)
-19.04%
π Share price
$0.01 AUD
π LIFE SCIENCES TOOLS & SERVICES